Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 26, 2023; 11(21): 4975-4988
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.4975
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.4975
Pre stool donation screening | Exclusion criteria for stool donation |
Current illness or exposure to endemic illness in the last 6 mo | Viral or bacterial illness in the week prior to donation, persistent fever, a visit in the last 6 mo to a country with an endemic infectious disease including parasitic diseases and traveler’s diarrhea |
Malignancy or gastrointestinal disease | Malignant disease (current or past), personal or family history of inflammatory bowel disease, personal history of IBS or symptoms of IBS, or celiac disease |
Hepatitis risk and the risk of sexually transmitted infection | Tattoo or piercing or blood transfusion within 6 mo prior to donation, casual unprotected sexual intercourse within 3 mo prior to donation or previous sexual contact with an intravenous drug user or sex worker. Sexual contact with a person infected with HTLV or HIV or hepatitis in the previous 6 mo |
Chronic disease | Chronic liver disease, neurological or autoimmune or rheumatological or hematological or metabolic or endocrine (aside from Hashimoto’s disease) or heart or lung or atopic disease. Chronic pain or chronic fatigue syndromes. Previous malaria diagnosis or rare infectious disease |
Surgical history | Previous gastrointestinal surgery, recipient of transplanted tissue |
Medication history | Any long-term medication use or short-term use of immunosuppressive medication or probiotics, antibiotics use within the previous 6 mo, current or previous chemotherapy, previous recipient of growth hormone or recipient of a live attenuated virus injection in the last 3 mo |
Illicit drug history | Previous illicit drug use (mariuana is an exclusion only if used within 3 mo of donation) |
Test type | Test name |
Blood tests | Complete blood count |
Urea and electrolytes including calcium | |
Glucose | |
Liver function testing | |
Lipid studies | |
Thyroid stimulating hormone | |
Hepatitis A, B and C, HTLV, HIV and cytomegalovirus serology | |
Syphilis testing | |
Strongyloides stercoralis serology | |
Immunoglobulin A level and anti- tissue transglutaminase serology | |
Antinuclear antibodies | |
Stool testing | Stool culture including bacteria, viruses and parasites |
CDI culture including vancomycin resistant CDI | |
Calprotectin ESBL and cryptosporidium calprotectin | |
Helicobacter antigen | |
Nasal swab | Methicillin resistant staphylococcus aureus and carbapenem resistant enterobacteriaceae screening |
EHEC | |
ESBL EHEC |
Host-related factors | Donor-related factors | Procedure-related factors |
Chronic dysbiosis state[94,95] | Donor genetics | Preconditioning of the gut: Various diets, fermented foods, prebiotics, probiotics, steroids and phage therapy[100] |
Host immunity state, determined by the host genetics[98], creates a hostile "hostile" microbiota environment | ‘Super-donors’[102] | Treatment-related protocols: Single donor vs multi-donors, route of administration of FMT (upper GI vs lower GI), the total number of FMT treatments administered (one to repeated), FMT preparation (anaerobic vs aerobic)[101] |
Donor species richness of microbiome[99] | Industry microbiota suspensions[106] | |
Donor microbiota stability and species evenness[103] |
- Citation: Kriger-Sharabi O, Malnick SDH, Fisher D. Manipulation of the intestinal microbiome-a slow journey to primetime. World J Clin Cases 2023; 11(21): 4975-4988
- URL: https://www.wjgnet.com/2307-8960/full/v11/i21/4975.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i21.4975